221 related articles for article (PubMed ID: 25602245)
21. Measurement of Developmental and Behavioral Concerns in Toddlers With Tuberous Sclerosis Complex.
McDonald NM; Jacobs S; Hyde C; Kasari C; Jeste SS
Pediatr Neurol; 2024 Jun; 155():62-67. PubMed ID: 38603983
[TBL] [Abstract][Full Text] [Related]
22. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
23. Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project.
de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; D'Amato L; Beure d'Augères G; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Kingswood JC; Jansen AC;
J Neurodev Disord; 2020 Sep; 12(1):24. PubMed ID: 32873244
[TBL] [Abstract][Full Text] [Related]
24. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study.
Ebrahimi-Fakhari D; Mann LL; Poryo M; Graf N; von Kries R; Heinrich B; Ebrahimi-Fakhari D; Flotats-Bastardas M; Gortner L; Zemlin M; Meyer S
Orphanet J Rare Dis; 2018 Jul; 13(1):117. PubMed ID: 30016967
[TBL] [Abstract][Full Text] [Related]
25. Tuberous Sclerosis Complex Patients' Needs and Difficulties-Results of TAND Questionnaire Analysis in Polish Adult Population.
Marcinkowska AB; Jóźwiak S; Tarasewicz A; Dębska-Ślizień A; Szurowska E
J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362764
[TBL] [Abstract][Full Text] [Related]
26. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.
de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Kingswood JC; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2018 Sep; 13(1):157. PubMed ID: 30201051
[TBL] [Abstract][Full Text] [Related]
27. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
Northrup H; Aronow ME; Bebin EM; Bissler J; Darling TN; de Vries PJ; Frost MD; Fuchs Z; Gosnell ES; Gupta N; Jansen AC; Jóźwiak S; Kingswood JC; Knilans TK; McCormack FX; Pounders A; Roberds SL; Rodriguez-Buritica DF; Roth J; Sampson JR; Sparagana S; Thiele EA; Weiner HL; Wheless JW; Towbin AJ; Krueger DA;
Pediatr Neurol; 2021 Oct; 123():50-66. PubMed ID: 34399110
[TBL] [Abstract][Full Text] [Related]
28. Development and Feasibility of the Self-Report Quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ).
Heunis TM; Chambers N; Vanclooster S; Bissell S; Byars AW; Capal JK; Cukier S; Davis PE; de Vries MC; De Waele L; Flinn J; Gardner-Lubbe S; Gipson T; Kingswood JC; Krueger DA; Kumm AJ; Sahin M; Schoeters E; Smith C; Srivastava S; Takei M; van Eeghen AM; Waltereit R; Jansen AC; de Vries PJ
Pediatr Neurol; 2023 Oct; 147():101-123. PubMed ID: 37598571
[TBL] [Abstract][Full Text] [Related]
29. Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).
Alperin S; Krueger DA; Franz DN; Agricola KD; Stires G; Horn PS; Capal JK
J Neurodev Disord; 2021 Dec; 13(1):60. PubMed ID: 34903167
[TBL] [Abstract][Full Text] [Related]
30. Is It Feasible to Identify Natural Clusters of TSC-Associated Neuropsychiatric Disorders (TAND)?
Leclezio L; Gardner-Lubbe S; de Vries PJ
Pediatr Neurol; 2018 Apr; 81():38-44. PubMed ID: 29530301
[TBL] [Abstract][Full Text] [Related]
31. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
32. Tuberous sclerosis complex is a novel, amyloid-independent tauopathy associated with elevated phosphorylated 3R/4R tau aggregation.
Liu AJ; Lusk JB; Ervin J; Burke J; O'Brien R; Wang SJ
Acta Neuropathol Commun; 2022 Mar; 10(1):27. PubMed ID: 35241183
[TBL] [Abstract][Full Text] [Related]
33. Neuropsychiatric comorbidities in tuberous sclerosis complex patients with epilepsy: results of the TAND checklist survey.
Lee HY; Lin CH; Wang XA; Tsai JD
Acta Neurol Belg; 2024 Jun; 124(3):973-979. PubMed ID: 38523222
[TBL] [Abstract][Full Text] [Related]
34. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
35. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
Gipson TT; Johnston MV
F1000Res; 2017; 6():. PubMed ID: 28663780
[TBL] [Abstract][Full Text] [Related]
36. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
37. The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex.
Wong M
J Neurodev Disord; 2019 Dec; 11(1):30. PubMed ID: 31838997
[TBL] [Abstract][Full Text] [Related]
38. The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review.
Vanclooster S; Bissell S; van Eeghen AM; Chambers N; De Waele L; Byars AW; Capal JK; Cukier S; Davis P; Flinn J; Gardner-Lubbe S; Gipson T; Heunis TM; Hook D; Kingswood JC; Krueger DA; Kumm AJ; Sahin M; Schoeters E; Smith C; Srivastava S; Takei M; Waltereit R; Jansen AC; de Vries PJ
J Neurodev Disord; 2022 Feb; 14(1):13. PubMed ID: 35151277
[TBL] [Abstract][Full Text] [Related]
39. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial.
Randell E; McNamara R; Davies DM; Owen-Jones E; Kirby N; Angel L; Drew C; Cannings-John R; Smalley M; Saxena A; McDermott E; Stockwell L; de Vries PJ; Hood K; Sampson JR
Trials; 2016 Aug; 17():398. PubMed ID: 27515417
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis complex: Recent advances in manifestations and therapy.
Wataya-Kaneda M; Uemura M; Fujita K; Hirata H; Osuga K; Kagitani-Shimono K; Nonomura N;
Int J Urol; 2017 Sep; 24(9):681-691. PubMed ID: 28667702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
